Pemphigus IgG causes skin splitting in the presence of both desmoglein 1 and desmoglein 3

被引:46
作者
Spindler, Volker
Drenckhahn, Detlev
Zillikens, Detlef
Waschke, Jens
机构
[1] Univ Wurzburg, Inst Anat & Cell Biol, D-97070 Wurzburg, Germany
[2] Med Univ Lubeck, Dept Dermatol, D-23538 Lubeck, Germany
关键词
D O I
10.2353/ajpath.2007.070028
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
According to the desmoglein (Dsg) compensation concept, different epidermal cleavage planes observed in pemphigus vulgaris and pemphigus foliaceus have been proposed to be caused by different autoantibody profiles against the desmosomal proteins Dsg 1 and Dsg 3. According to this model, Dsg 1 autoantibodies would only lead to epidermal splitting in those epidermal layers in which no Dsg 3 is present to compensate for the functional loss of Dsg 1. We provide evidence that both pemphigus foliaceus-IgG containing Dsg 1- but not Dsg 3-specific antibodies and pemphigus vulgaris-IgG with antibodies to Dsg 1 and Dsg 3 were equally effective in causing epidermal splitting in human skin and keratinocyte dissociation in vitro. These effects were present where keratino-cytes expressed both Dsg 1 and Dsg 3, demonstrating that Dsg 3 does not compensate for Dsg 1 inactivation. Rather, the cleavage plane in intact human skin caused by pemphigus autoantibodies was similar to the plane of keratinocyte dissociation in response to toxin B-mediated inactivation of Rho GTPases. Because we recently demonstrated that pemphigus-IgG causes epidermal splitting by inhibition of Rho A, we propose that Rho GTPase inactivation contributes to die mechanisms accounting for the cleavage plane in pemphigus skin splitting.
引用
收藏
页码:906 / 916
页数:11
相关论文
共 34 条
[1]   Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just 'witnesses of disease'? [J].
Amagai, M. ;
Ahmed, A. R. ;
Kitajima, Y. ;
Bystryn, J. C. ;
Milner, Y. ;
Gniadecki, R. ;
Hertl, M. ;
Pincelli, C. ;
Fridkis-Hareli, M. ;
Aoyama, Y. ;
Frusic-Zlotkin, M. ;
Mueller, E. ;
David, M. ;
Mimouni, D. ;
Vind-Kezunovic, D. ;
Michel, B. ;
Mahoney, M. ;
Grando, S. .
EXPERIMENTAL DERMATOLOGY, 2006, 15 (10) :815-831
[2]   Desmoglein as a target in autoimmunity and infection [J].
Amagai, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (02) :244-252
[3]   The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile [J].
Amagai, M ;
Tsunoda, K ;
Zillikens, D ;
Nagai, T ;
Nishikawa, T .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 40 (02) :167-170
[4]  
Amagai M, 1999, BRIT J DERMATOL, V140, P351
[5]   Pemphigus vulgaris antigen (Desmoglein 3) is localized in the lower epidermis, the site of blister formation in patients [J].
Amagai, M ;
Koch, PJ ;
Nishikawa, T ;
Stanley, JR .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (02) :351-355
[6]  
Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO
[7]  
2-4
[8]   Pemphigus vulgaris IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells [J].
Aoyama, Y ;
Kitajima, Y .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 112 (01) :67-71
[9]   Desmosome signaling - Inhibition of p38MAPK prevents pemphigus vulgaris IgG-induced cytoskeleton reorganization [J].
Berkowitz, P ;
Hu, PQ ;
Liu, Z ;
Diaz, LA ;
Enghild, JJ ;
Chua, MP ;
Rubenstein, DS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (25) :23778-23784
[10]   p38MAPK inhibition prevents disease in pemphigus vulgaris mice [J].
Berkowitz, Paula ;
Hu, Peiqi ;
Warren, Simon ;
Liu, Zhi ;
Diaz, Luis A. ;
Rubenstein, David S. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (34) :12855-12860